Type 1

ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day

Retrieved on: 
Thursday, March 7, 2024

The event included presentations by members of the ARS Pharma management team and by two distinguished allergists, Dr. Jonathan Spergel, M.D., Ph.D. and Dr. Thomas B. Casale, M.D.

Key Points: 
  • The event included presentations by members of the ARS Pharma management team and by two distinguished allergists, Dr. Jonathan Spergel, M.D., Ph.D. and Dr. Thomas B. Casale, M.D.
  • Of the patients that do fill their prescription, 80-90% either do not carry or use their treatment as indicated.
  • In late-February, the Company announced positive clinical data from a Phase 2 trial evaluating neffy in adults with chronic spontaneous urticaria.
  • The webcast replay and accompanying slides from today’s investor event may be accessed through the Events & Presentations page in the Investors & Media section of the Company's website.

Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update

Retrieved on: 
Friday, February 23, 2024

Nine patients were treated in the study (30 M group, n=3; 60 M group, n=4; 90 M group (optimal dose), n=2).

Key Points: 
  • Nine patients were treated in the study (30 M group, n=3; 60 M group, n=4; 90 M group (optimal dose), n=2).
  • Although the study was not powered to reliably demonstrate efficacy, median overall survival (OS) of patients in the study was 16.5 months.
  • This compares favourably with median survival rate in a cohort of 316 cases of 10.0 months (Jansen et al, 2015.
  • The results of the experiment were inconclusive in that they did not correlate with the results previously seen in in vitro and in vivo studies of tolimidone.

Nium Becomes First Global Fintech to Secure Coveted Type 1 Funds Transfer License from Japan's Financial Service Agency

Retrieved on: 
Thursday, February 29, 2024

SINGAPORE, Feb. 29, 2024 /PRNewswire/ -- Nium, the leader in real-time cross-border payments, announced today that it is the first non-Japanese company to have secured a Type 1 Funds Transfer Service Provider (FTSP) license from the Japanese Financial Services Agency (JFSA). The Type 1 license authorizes Nium to provide a wide range of financial services, including transferring up to 50 million JPY per transaction via Zengin-Net, Japan's local payment clearing rail, to a Japanese beneficiary account.

Key Points: 
  • In 2021, an amendment to Japan's Payment Services Act lifted cross-border transfer caps for Type 1 license holders, to lower the cost of money transfers in and out of the country.
  • However, since this amendment passed, few companies have been able to meet the high standards for regulatory approval.
  • Most other non-bank entities, including Money Service Businesses, hold Type 2 licenses, which limits cross border transfers to only 1 million JPY.
  • This accomplishment aligns with Nium's commitment to redefining global financial services by providing users with unparalleled access to secure and innovative payment solutions.

Nium Becomes First Global Fintech to Secure Coveted Type 1 Funds Transfer License from Japan's Financial Service Agency

Retrieved on: 
Thursday, February 29, 2024

SINGAPORE, Feb. 28, 2024 /PRNewswire/ -- Nium, the leader in real-time cross-border payments, announced today that it is the first non-Japanese company to have secured a Type 1 Funds Transfer Service Provider (FTSP) license from the Japanese Financial Services Agency (JFSA). The Type 1 license authorizes Nium to provide a wide range of financial services, including transferring up to 50 million JPY per transaction via Zengin-Net, Japan's local payment clearing rail, to a Japanese beneficiary account.

Key Points: 
  • In 2021, an amendment to Japan's Payment Services Act lifted cross-border transfer caps for Type 1 license holders, to lower the cost of money transfers in and out of the country.
  • However, since this amendment passed, few companies have been able to meet the high standards for regulatory approval.
  • Most other non-bank entities, including Money Service Businesses, hold Type 2 licenses, which limits cross border transfers to only 1 million JPY.
  • This accomplishment aligns with Nium's commitment to redefining global financial services by providing users with unparalleled access to secure and innovative payment solutions.

Beyond Type 1 Announces New Board Members and Executive Team

Retrieved on: 
Thursday, February 15, 2024

SAN MATEO, Calif., Feb. 15, 2024 /PRNewswire/ -- Beyond Type 1 today announced three new board members and four new executives to lead the organization as it grows its program, community, and partner network in 2024.

Key Points: 
  • "Their diverse expertise and unwavering dedication to serving people with diabetes will be instrumental in driving our initiatives forward.
  • They each share an important passion and personal connection to the work of Beyond Type 1."
  • The new members of Beyond Type 1's Board of Directors comprise a diverse set of senior leaders across multiple industries who are all united in their commitment to fighting diabetes.
  • Beyond Type 1 also welcomed four accomplished executives to its leadership team , bringing decades of combined expertise across healthcare, technology, marketing, creative, and operations.

Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients

Retrieved on: 
Thursday, February 8, 2024

CARDIFF, United Kingdom, February 8, 2024 (GLOBE NEWSWIRE) -- Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs including Type 1 diabetes and rare/orphan brain cancers, today provided survival updates from its MAGIC-G1 study (NCT05324501) of MTX110 in patients with recurrent glioblastoma (“rGBM”) being conducted at Duke Cancer Institute and Baptist MD Anderson Cancer Center.

Key Points: 
  • In October 2023, Biodexa announced completion of recruitment of Cohort A of an ongoing open-label Phase I dose-escalation study designed to assess the feasibility and safety of intermittent infusions of MTX110 administered by convection enhanced delivery (“CED”) via implanted refillable pump and catheter.
  • Because no drug-related adverse events were observed within the first 30 days from start of treatment, the minimum number of four patients were recruited into Cohort A.
  • Patients #2, 3 and 4 each received weekly infusions of 90µM of MTX110, the expected optimum dose, and remain in the study.
  • GBM universally recurs and once it does median overall survival according to a retrospective analysis of 299 patients reported in the Journal of Neuro-Oncology is 6.5 months1.

Biodexa Announces Allowance of U.S. Patent Covering Tolimidone

Retrieved on: 
Wednesday, February 7, 2024

CARDIFF, United Kingdom, February 7, 2024 (GLOBE NEWSWIRE) -- Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”)(Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs including Type 1 diabetes (“T1D”) and rare/orphan brain cancers, today announced that the U.S. Patent and Trademark Office allowed U.S. patent application No. 16/546,595 titled “Prevention of Pancreatic Cell Degeneration” which was exclusively licensed to Biodexa by Melior Pharmaceuticals, Inc., along with other patents, in a transaction which closed in December 2023.

Key Points: 
  • Biodexa Announces Allowance of U.S. Patent Covering Tolimidone
    Biodexa plans to initiate a Phase 2 clinical program of tolimidone in Type 1 diabetes, following several preclinical studies demonstrating its role in beta cell survival
    CARDIFF, United Kingdom, February 7, 2024 (GLOBE NEWSWIRE) -- Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”)(Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs including Type 1 diabetes (“T1D”) and rare/orphan brain cancers, today announced that the U.S. Patent and Trademark Office allowed U.S. patent application No.
  • 16/546,595 titled “Prevention of Pancreatic Cell Degeneration” which was exclusively licensed to Biodexa by Melior Pharmaceuticals, Inc., along with other patents, in a transaction which closed in December 2023.
  • Stephen Stamp, CEO and CFO of Biodexa, commented “This soon-to-be-issued patent is expected to provide market exclusivity for tolimidone in the U.S. and underpins our investment thesis in ongoing preclinical studies and an upcoming Phase 2 program in Type 1 diabetes patients which we expect to start in next quarter.”

SOLOWIN HOLDINGS Debuts in Investor Conferences in San Juan and Atlantic City

Retrieved on: 
Thursday, February 1, 2024

HONG KONG, Feb. 01, 2024 (GLOBE NEWSWIRE) -- SOLOWIN HOLDINGS (Nasdaq: SWIN) (“SOLOWIN” or the “Company”), one of the few Chinese investor-focused and versatile securities brokerage companies based in Hong Kong, debuted in two recent major investment conferences by delivering compelling presentations and engaging in one-on-one meetings with investors at the Sequire Investor Summit, in San Juan, Puerto Ric, from January 23 to 25, 2024, and The Microcap Conference, in Atlantic City, New Jersey from January 30 to February 1, 2024.

Key Points: 
  • During the conferences, the Company highlighted the recent development of its virtual asset business.
  • This successful license uplift allows the Company to expand its business scope to provide both traditional securities dealing services and virtual asset trading services.
  • While cryptocurrency proves to be a promising asset class, it’s imperative to guarantee safety for all participants in the trading process.
  • We will be dedicated to delivering secure and regulated virtual asset services to our valued customers.”

MDB Capital Holdings Issues Annual Letter to Shareholders

Retrieved on: 
Wednesday, January 31, 2024

Addison, TX, Jan. 31, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, today released its annual letter to shareholders from its CEO and Co-Founder, Christopher Marlett.

Key Points: 
  • Addison, TX, Jan. 31, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, today released its annual letter to shareholders from its CEO and Co-Founder, Christopher Marlett.
  • To the Shareholders of MDB Capital Holdings, LLC:
    Welcome to our first annual letter, which I plan to send every January to reflect on the past year and how what we learned will shape our plans for the following year.
  • Undervalued Public Companies: We identify and partner with more mature public companies with undervalued technologies that possess significant leadership potential.
  • We then combine that with our community of experienced investors that commit not only their monetary capital, but their intellectual capital to help each company succeed.

Appfire Exceeds $200M in ARR, Signaling Growing Demand for Software that Augments Leading Platforms for Modern Work

Retrieved on: 
Tuesday, January 30, 2024

BOSTON, Jan. 30, 2024 /PRNewswire/ -- Appfire, the leading global provider of software that enhances, extends, and connects the world's leading platforms such as Atlassian, Microsoft, monday.com, and Salesforce, today announced a strong year of growth in 2023, achieving $200 million in Annual Recurring Revenue (ARR). The company's mission to equip and connect every team so they can plan and deliver their best work has continued to prove successful producing consistent year-over-year (YoY) growth – with Appfire growing from $10M ARR to $200M ARR in the last four years. Appfire has also been profitable since inception with best-in-class free cash flow margins relative to the broader SaaS universe.

Key Points: 
  • Appfire has also been profitable since inception with best-in-class free cash flow margins relative to the broader SaaS universe.
  • Our success would not be possible without the work and dedication of our team, partners, and customers."
  • The company also continued its commitment to Pledge 1% for all four pledge types: product, profit, equity, and employee time.
  • For more on Appfire, visit www.appfire.com and follow along on X (Twitter) , LinkedIn , Life at Appfire , and Instagram .